-
Mashup Score: 0
The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We are continuing to highlight noteworthy research from #ASCO23! Next up, watch @OmidHamidMD, of @angelesclinic, discuss phase 1 findings with fianlimab plus cemiplimab in patients with advanced melanoma. @ASCO #melsm https://t.co/fSpDpEVMQQ https://t.co/u4J9hXwJAx
-
-
Mashup Score: 0Loss of Y Chromosome in Men Enables Cancer to Grow - 1 year(s) ago
Cedars-Sinai Cancer investigators elucidate how this process allows bladder tumors to evade the immune system but also makes them vulnerable to a common treatment.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Loss of Y Chromosome in Men Enables Cancer to Grow @CedarsSinai #oncology #MedTwitter https://t.co/rgfvqDrJed
-
-
Mashup Score: 0
The allogeneic CAR T-cell therapy CB-010 demonstrated early signs of durable antitumor activity and favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CB-010 Elicits 94% ORR in Relapsed/Refractory Non-Hodgkin Lymphoma @MDAndersonNews #lymsm #oncology https://t.co/G0RhHnmZ9i
-
-
Mashup Score: 0FDA Awards Orphan Drug Designation to Gallium Maltolate for Pediatric Glioblastoma Multiforme - 1 year(s) ago
The FDA has granted an orphan drug designation to gallium maltolate for use as a potential therapeutic option in pediatric patients with glioblastoma multiforme.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Awards Orphan Drug Designation to Gallium Maltolate for Pediatric Glioblastoma Multiforme #btsm https://t.co/1C4sati5J3
-
-
Mashup Score: 0Dr Masarova on the Rationale for Investigating Ropeginterferon Alfa-2b in Essential Thrombocythemia - 1 year(s) ago
Lucia Masarova, MD, discusses the single-arm multicenter phase 2 EXCEED-ET trial of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our excitement from #ASCO23 is still going strong! See @MDmasarova, of @MDAndersonNews, discuss the design for the phase 1/2 EXCEED-ET trial in patients with essential thrombocythemia! @ASCO #oncology https://t.co/gHiU86w2c9 https://t.co/B97L4NMGuM
-
-
Mashup Score: 1
China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab plus for the first-line treatment of patients with unresectable or metastatic renal cell carcinoma
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab plus for the first-line treatment of patients with unresectable or metastatic RCC. #kcsm #oncology https://t.co/cNQiZKxuVh
-
-
Mashup Score: 0
China’s National Medical Products Administration has approved trastuzumab deruxtecan monotherapy in adult patients with unresectable or metastatic HER2-low breast cancer who have previously received a systemic therapy in the metastatic setting or whose disease recurred during or within 6 months of adjuvant chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
China’s NMPA has approved trastuzumab deruxtecan based on findings from the DESTINY-Breast04 trial, in which trastuzumab deruxtecan treatment reduced the risk of disease progression or death by 50% vs physician’s choice of chemotherapy. #bcsm #oncology https://t.co/oVFbS52VyU https://t.co/woSlIfqGJb
-
-
Mashup Score: 0BASECAMP-1 Trial Aims to Identify Patients for Subsequent Treatment Trial of CAR T-Cell Therapy in Solid Tumors - 1 year(s) ago
Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert and dives into the unique mechanism of action of A2B530. @mgfakih @cityofhope #oncology https://t.co/5X3enXUawX
-
-
Mashup Score: 0
Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
JAK inhibitor add-on agents may address an unmet need for patients with myelofibrosis with disease- or treatment-related anemia, as standard myelofibrosis treatments can cause AEs that interfere with patient quality of life @fredhutch #mpnsm #oncology https://t.co/KcT2Nn5TJc https://t.co/4DCzU1nAtH
-
Setanaxib Plus Pembrolizumab Elicits PFS Benefit in Recurrent or Metastatic HNSCC #hncsm #oncology https://t.co/5P6PflcoON